Heart Drug Misses Mark in Key Study
A new medicine from Novartis did not help patients avoid heart attacks or strokes in its most important test.
Many people hoped a new drug could make hearts healthier. Novartis worked hard on this medicine. It aimed to lower a bad fat in the blood called Lp(a). Doctors know this fat can cause heart problems. They watched this study closely.
Novartis tested the drug in a large group of people. This was a phase 3 study, which is the final big test. The goal was to see if the drug could stop heart attacks, strokes, or other major heart issues. The results came out, and the drug did not meet this goal. It did not reduce these serious health risks.
This news is a setback for patients and doctors. Lp(a) is a tricky problem. Finding a way to treat it remains a big challenge. Researchers will keep looking for new answers to protect hearts from this silent danger.
Source: FierceBiotech
More from Biotech
